BEAM vs APPN Comparison

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.